(PDF) The CDK4/6 Inhibitor Abemaciclib Induces a T Cell

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell Reports - United States

doi 10.1016/j.celrep.2018.02.053

Related search

Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune Checkpoint Blockade

Clinical Cancer Research

Cancer Research

English

P1.04-07 Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 Blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms

Journal of Thoracic Oncology

Respiratory Medicine

English

MA11.01 Comparative Efficacy of T-Cell Intrinsic Versus Extrinsic PD-1 Blockade to Overcome PD-L1+ Tumor-Mediated Exhaustion

Journal of Thoracic Oncology

Respiratory Medicine

English

PD-L1 Checkpoint Blockade Delivered by Retroviral Replicating Vector Confers Anti-Tumor Efficacy in Murine Tumor Models

English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

English

Glioblastoma-Derived IL-6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth

Clinical Cancer Research

Cancer Research

English

Combination of Chemotherapy and PD-1 Blockade Induces T Cell Responses to Tumor Non-Mutated Neoantigens

Communications Biology

Molecular Biology

Biological Sciences

English

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-Pd-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

Journal of Cancer

English

A Novel Tankyrase Inhibitor, MSC2504877, Enhances the Effects of Clinical CDK4/6 Inhibitors

Scientific Reports

Multidisciplinary

English